Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Show more

Darwinweg 24, Leiden, 2333 CR, Netherlands

https://www.pharming.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

767.9M

52 Wk Range

$9.62 - $21.34

Previous Close

$10.85

Open

$11.08

Volume

6,391

Day Range

$10.78 - $11.15

Enterprise Value

712.3M

Cash

158.3M

Avg Qtr Burn

-9.658M

Insider Ownership

0.00%

Institutional Own.

0.14%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Joenja® (leniolisib) Details Activated Phosphoniositide 3-kinase Delta Syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ruconest (C1 Inhibitor) Details Acute Hereditary Angioedema Attacks	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leniolisib Details Activated Phosphoniositide 3-kinase Delta Syndrome (APDS in children 4–11) (label expansion)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KL1333 Details Mitochondrial disease, primary mitochondrial myopathies	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leniolisib Details Immunodeficiency	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.